Subscribe
millefloreimages-istockphoto-com-breast-cancer-
MillefloreImages / iStockphoto.com
31 July 2017Americas

AstraZeneca and Merck enter $8.5bn cancer therapy collaboration

AstraZeneca has entered into an oncology collaboration with Merck, under which the companies will co-develop AstraZeneca’s Lynparza (olaparib).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment
30 July 2020   Biopharmaceutical company AstraZeneca has struck a deal with Japanese pharmaceutical company Daiichi Sankyo to jointly develop and market a new medicine to treat lung, breast and other cancers.
Americas
Italian research organisation extends collaboration with Merck & Co
5 September 2018   Italy-based research organisation IRBM has signed a new agreement with Merck & Co in the peptides therapeutics area, extending the parties’ long-standing collaboration.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment
30 July 2020   Biopharmaceutical company AstraZeneca has struck a deal with Japanese pharmaceutical company Daiichi Sankyo to jointly develop and market a new medicine to treat lung, breast and other cancers.
Americas
Italian research organisation extends collaboration with Merck & Co
5 September 2018   Italy-based research organisation IRBM has signed a new agreement with Merck & Co in the peptides therapeutics area, extending the parties’ long-standing collaboration.

More on this story

Big Pharma
AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment
30 July 2020   Biopharmaceutical company AstraZeneca has struck a deal with Japanese pharmaceutical company Daiichi Sankyo to jointly develop and market a new medicine to treat lung, breast and other cancers.
Americas
Italian research organisation extends collaboration with Merck & Co
5 September 2018   Italy-based research organisation IRBM has signed a new agreement with Merck & Co in the peptides therapeutics area, extending the parties’ long-standing collaboration.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB